Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Refractory Solid Tumors with High T Cell Inflamed GEP Score
NCT07300891Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07300891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300891.